TY - JOUR
T1 - The systemic antiangiogenic effect of intravitreal aflibercept injection in a mouse model of retinopathy of prematurity
AU - Ichiyama, Yusuke
AU - Obata, Shumpei
AU - Saishin, Yoshitsugu
AU - Sawada, Osamu
AU - Kakinoki, Masashi
AU - Sawada, Tomoko
AU - Kubota, Yoshiaki
AU - Ohji, Masahito
N1 - Funding Information:
We thank Fumiko Kimura for her technical support. This work was supported by grants‐in‐aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (19K18877) and by research grants from Alcon and Novartis. These funding organizations had no role in the design or conduct of this study.
Publisher Copyright:
© 2021 Federation of American Societies for Experimental Biology
PY - 2021/3
Y1 - 2021/3
N2 - Retinopathy of prematurity (ROP) is a leading cause of childhood blindness and intravitreal anti-vascular endothelial growth factor (VEGF) injection is becoming a first-line choice for treatment of ROP. However, there is a major concern that intravitreally injected anti-VEGF agents could escape from the eye into the systemic circulation and impair systemic development. Moreover, escaped anti-VEGF agents could have an effect on the retina of the fellow eye. In this study, we investigated the hematogenous effect of a single intravitreal anti-VEGF injection in a mouse model of ROP. Here, we showed that single intravitreal aflibercept injection to one eye can affect body weight gain, the fellow eye, and renal vessels, although no apparent effect was observed in brain vessels. Furthermore, this hematogenous effect was dose-dependent. Our results provide very important insights into the clinical use of anti-VEGF agents for ROP treatment.
AB - Retinopathy of prematurity (ROP) is a leading cause of childhood blindness and intravitreal anti-vascular endothelial growth factor (VEGF) injection is becoming a first-line choice for treatment of ROP. However, there is a major concern that intravitreally injected anti-VEGF agents could escape from the eye into the systemic circulation and impair systemic development. Moreover, escaped anti-VEGF agents could have an effect on the retina of the fellow eye. In this study, we investigated the hematogenous effect of a single intravitreal anti-VEGF injection in a mouse model of ROP. Here, we showed that single intravitreal aflibercept injection to one eye can affect body weight gain, the fellow eye, and renal vessels, although no apparent effect was observed in brain vessels. Furthermore, this hematogenous effect was dose-dependent. Our results provide very important insights into the clinical use of anti-VEGF agents for ROP treatment.
KW - anti-vascular endothelial growth factor
KW - fellow eye
KW - hematogenous effect
KW - retinopathy of prematurity
KW - systemic effect
UR - http://www.scopus.com/inward/record.url?scp=85101484856&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101484856&partnerID=8YFLogxK
U2 - 10.1096/fj.202002414R
DO - 10.1096/fj.202002414R
M3 - Article
C2 - 33566381
AN - SCOPUS:85101484856
SN - 0892-6638
VL - 35
JO - FASEB Journal
JF - FASEB Journal
IS - 3
M1 - e21390
ER -